Regulators appear to be increasingly prepared to let AI handle routine, low-risk research tasks with minimal friction, while keeping firm human control over decisions that directly shape safety, ethics, and public trust. If they stay on this course, international coordination and iterative learning between agencies will not just keep up with AI, they will shape it. The result is substantial: more efficient drug development, lower costs, and more timely, representative access to better therapies. The challenge, which we cannot underestimate, is to ensure that the governance, safeguards, and ethical commitments evolve as quickly as the technology they aim to oversee. Help keep us going by donating now.